Consumer telehealth · Weight-care / GLP-1
GobyMeds
GobyMeds is a cash-pay consumer telehealth brand for compounded GLP-1 weight care and related wellness medications with published starter pricing. It is not a hospital or insurance-billed obesity clinic network.
Strong fit
- Cash-pay adults comparing published low monthly compounded GLP-1 starter bundles
- Patients who want transparent no-membership pricing and HSA/FSA-friendly checkout
- Buyers evaluating budget DTC weight peers on the same board as Eden and Found
Weak fit
- Patients who need insurance-billed obesity medicine with longitudinal coaching
- People who require only FDA brand-name GLP-1s with no compounded discussion
- Buyers who need a large national clinical brand with extensive published outcomes research
Bottom line
GobyMeds earns a Conditional on our consumer weight-care board. The Delaware-based telehealth brand led by founder and CEO Justin McCombs markets compounded semaglutide and tirzepatide bundles with published starter pricing and claims of 75,000-plus patients. Transparent cash-pay menus are the main draw; clinician quality, pharmacy partners, and long-term follow-up still vary by case and need verification. Public scale markers are thinner than Found or Eden. Score sits at the bottom of this weight-care board as a budget option worth considering only when published price and simple online intake are the buying constraints.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
GobyMeds is a cash-pay consumer telehealth brand for compounded GLP-1 weight care and related wellness medications, led by founder and CEO Justin McCombs. The public site emphasizes transparent pricing, online intake, and shipping to the door.
It is a DTC product vendor, not a hospital. Compare Eden and Fridays when a broader clinician-branded program matters more, Found when coaching-led metabolic care is the frame, and Henry Meds when compounded weight-loss peers are the only comparison set.
Score is Conditional because follow-up depth and brand clinical evidence are thinner than higher-scored weight peers, even though pricing clarity is strong.
Competitor landscape
| Vendor | Overall | Ease of use |
|---|---|---|
| Found | 7.4 | 7.2 |
| Eden | 7.3 | 7.2 |
| Fridays | 7.1 | 7.0 |
| Mochi Health | 7.0 | 6.6 |
| Nu Image Medical | 6.8 | 6.5 |
| Henry Meds | 6.7 | 6.3 |
| GobyMeds | 6.6 | 6.5 |
Pricing
| Item | Detail |
|---|---|
| Model | Cash-pay compounded GLP-1 bundles and related wellness meds with published starter prices; no membership fee messaging on the marketing site. |
| What usually drives cost | Drug (semaglutide vs tirzepatide), bundle length, dose, and add-on therapies such as NAD+ or sermorelin. |
| What to ask in diligence | All-in cost for your first three months including clinician review, medication, and shipping. |
| Published pricing | Public list price: compounded semaglutide starter bundles advertised from about $99/month equivalent; tirzepatide higher; confirm live checkout. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get GobyMeds to function | |
| Honest eligibility and medication history ready for clinician review | Incomplete intake delays or blocks prescribing. |
| Clear budget for cash-pay medication and visits | Surprise totals drive abandonment. |
| Plan for injection training or oral alternatives if offered | Unprepared patients stall after ship. |
| Shipping address and cold-chain expectations confirmed | Failed delivery wastes medication. |
| Follow-up cadence the patient will actually keep | One-time fills without check-ins weaken results. |
| What will maximize your value | |
| Complete labs or required screening before dose escalation | Skipping gates raises safety risk. |
| Track weight, side effects, and adherence weekly for 90 days | App opens are not outcomes. |
| Use one pharmacy path; avoid duplicate telehealth scripts | Split sourcing confuses dosing. |
| Message the care team early on nausea or supply gaps | Silent side effects cause drop-off. |
| Re-price the plan at each refill before autopay | Dose changes alter monthly cost. |
| Deal-breakers | |
| You need insurance-only obesity care and refuse cash-pay models. | |
| A clinician determines GLP-1 therapy is inappropriate. | |
| You cannot receive or store refrigerated medication safely. | |
| You will not complete required follow-up or screening. | |
| You expect a hospital procedure pathway from a DTC telehealth brand. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Intake | 1-7 days - Quiz, history, eligibility. |
| 2 | Clinician review | 1-7 days - Approval or alternatives. |
| 3 | First shipment | 2-10 days - Pharmacy fill and delivery. |
| 4 | Titration & follow-up | 1-6 months - Dose changes and check-ins. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.